Sign In
Buy LLY
$1,169.86
+53.75 (+4.82%)
At Close: Aug 05, 2026
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
01:27pm, Monday, 27'th Oct 2025
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno
BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares
12:36pm, Monday, 27'th Oct 2025
BDF-GESTION sold 4,149 shares of Eli Lilly and Company; Transaction value was $3.1 million Transaction represents 0.37% of BDF-GESTION's 13F reportable assets under management Post-trade stake: 19,949
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
12:06pm, Monday, 27'th Oct 2025
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Down 15%, Should You Buy the Dip on Eli Lilly?
11:00am, Monday, 27'th Oct 2025
Eli Lilly is one of the largest drug companies in the world. The pharmaceutical giant's stock price is 15% below its 2024 high-water mark.
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
10:56am, Monday, 27'th Oct 2025
Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.
Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:17am, Monday, 27'th Oct 2025
Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarte
LLY Stock To $1,100?
09:25am, Monday, 27'th Oct 2025
Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca si
Should You Buy Eli Lilly Stock Before Oct. 30?
07:31am, Monday, 27'th Oct 2025
Wall Street expects good news when Lilly announces its Q3 results on Oct. 30. Lilly's stock might not perform as you think it will, even if it beats analysts' estimates.
Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its b
Eli Lilly: Is Another Monster Quarter Coming
08:15am, Sunday, 26'th Oct 2025
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stoc
Wall Street Week Ahead
07:01am, Sunday, 26'th Oct 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Pharmaceutical Stocks To Watch Now – October 24th
02:40am, Sunday, 26'th Oct 2025
Eli Lilly and Company, Wellgistics Health, Pfizer, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks a
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
10:31am, Friday, 24'th Oct 2025
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Eli Lilly to buy gene therapy developer Adverum in about $262 million deal
10:11am, Friday, 24'th Oct 2025
Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 million, aiming to strengthen its pipeline with an experimental eye disease tr
